

- **Name:** Eui Kyu Chie, MD, PhD
 - **Current Position & Affiliation:** Professor, Seoul National University
 - **Country:** Republic of Korea
-
- **Educational Background:**
 - M.D., Seoul National University College of Medicine
 - M.S., Seoul National University Graduate School
 - Ph.D., Seoul National University Graduate School
 - **Professional Experience:**
 - Assistant Clinical Professor, Department of Radiation Oncology, Seoul National University Hospital
 - Associate Professor/Professor, Department of Radiation Oncology, Seoul National University College of Medicine
 - **Professional Organizations:**
 - General Secretary, Korean Society for Radiation Oncology
 - Board member, Korean Cancer Association
 - Vice-chair, Korean Association for Radiation Protection
 - Director of Hospital Information, Korean Society of Medical Informatics
 - **Main Scientific Publications:**
 1. Kim K, Yu JI, Jung W & Chie EK. Role of adjuvant radiotherapy in extrahepatic bile duct cancer: a multicenter retrospective study (Korean Radiation Oncology Group 18-14). *Eur J Cancer*. 2021;157:31.
 2. Chang WI, Kim BH, Kang HC & Chie EK. The role of adjuvant chemoradiotherapy in non-hilar extrahepatic bile duct cancer: A long term single institutional analysis. *Int J Radiat Oncol Biol Phys*. 2021;111:395.
 3. Lee KH, Chie EK, Im SA et al. Phase II trial of postoperative adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiotherapy with gemcitabine in patients with resected pancreatic cancer. *Cancer Res Treat*. 2021;53:1096.
 4. Jeon SH, Lim YJ, Koh JM & Chie EK. A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8+ cells in locally advanced rectal cancer. *Radiother Oncol*. 2021;162:124-131.
 5. Kim BH, Kim K, Jang JY & Chie EK. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma. *Eur J Surg Oncol*. 2020;46:2122.
 6. Jeon SH, Chie EK, Kim YJ et al. Targeted next-generation DNA sequencing identifies Notch signaling pathway mutation as a predictor of radiation response. *Int J Radiat Biol*. 2019;95:1640.
 7. Jang BS, Park HJ, Kim K & Chie EK. Role of adjuvant chemoradiotherapy for duodenal cancer: An updated analysis of long-term follow-up from single institution. *World J Surg*. 2018;42:3294.
 8. Kim BH, Kim E, Kim K & Chie EK. The impact of perioperative CA19-9 change on the

- survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma. *J Surg Oncol.* 2018;117:380.
9. Kim BH, Kwon J, Chie EK et al. Adjuvant chemoradiotherapy is associated with improved survival for patients with resected gallbladder carcinoma: a systematic review and meta-analysis. *Ann Surg Oncol.* 2018;25:255.
 10. Kim YJ, Koh HK, Chie EK et al. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy. *Int J Clin Oncol* 2017;22:1069.
 11. Kim BH, Chie EK, Kim K et al. Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution. *Oncotarget.* 2017;8:78076.
 12. Koh HK, Chie EK, Kim K et al. Outcome analysis of chemoradiation in unresectable pancreatic cancer focusing on treatment sequencing strategy. *Anticancer Res.* 2016;36:5455.
 13. Kim K, Chie EK, Jang JY et al. Prognostic significance of nodal ratio in patients undergoing adjuvant chemoradiotherapy after curative resection for ampullary cancer. *Am J Clin Oncol* 2016;39:346.
 14. Chie EK, Shin JH, Kim JH et al. In vitro and in vivo radiosensitizing effect of valproic acid on fractionated irradiation. *Cancer Res Tr* 2015;47:527.
 15. Eom KY, Chie EK, Kim K et al. Postoperative chemoradiotherapy following pancreaticoduodenectomy: Impact of dose-volumetric parameters on the development of diabetes mellitus. *Strahlenther Onkol* 2013;189:753.
 16. Kim K, Min HS, Chie EK et al. CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. *World J Gastroenterol* 2013;19:1438.
 17. Kim K, Chie EK, Jang JY et al. Role of adjuvant chemoradiotherapy for duodenal cancer: A single center experience. *Am J Clin Oncol* 2012;35:533.
 18. Kim K, Chie EK, Jang JY et al. Distant metastasis risk stratification for patients undergoing curative resection followed by adjuvant chemoradiation for extrahepatic bile duct cancer. *Int J Radiat Oncol Biol Phys* 2012;84:81.
 19. Kim K, Chie EK, Jang JY et al. Prognostic significance of tumor location after adjuvant chemoradiotherapy for periampullary adenocarcinoma. *Clin Transl Oncol* 2012;14:391.
 20. Kim K, Chie EK, Jang JY et al. Postoperative chemoradiotherapy for gallbladder cancer. *Strahlenther Onkol* 2012;188:388.
 21. Kim K, Chie EK, Jang JY et al. Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience. *Am J Clin Oncol* 2012;35:136.
 22. Kim K, Chie EK, Jang JY et al. Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer? *Int J Radiat Oncol Biol Phys* 2010;77:1186.
 23. Kim K, Chie EK, Jang JY et al. Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. *Int J Radiat Oncol Biol Phys* 2009;75:436.
 24. Choi JH, Kim K, Chie EK et al. Does adjuvant radiotherapy suppress the liver regeneration after partial hepatectomy? *Int J Radiat Oncol Biol Phys* 2009;74:67.
 25. Kim K, Chie EK, Jang JY et al. Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil based chemoradiotherapy for pancreatobiliary cancer. *Jpn J Clin Oncol* 2009;39:111.